Journal of the National Comprehensive Cancer Network

Article	Citations
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology	718
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology	589
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021	579
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology	542
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology	520
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology	514
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology	500
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology	441
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology	440
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology	349
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology	338
NCCN Guidelines Insights: Rectal Cancer, Version 6.2020	290
Role of Immunotherapy in Triple-Negative Breast Cancer	286
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021	284
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020	278
Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal	262
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology	243
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology	238
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology	234
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology	180
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020	179
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021	172
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021	168
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022	168
NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021	163

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021	152
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021	149
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology	145
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology	133
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology	128
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology	122
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology	120
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021	107
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022	107
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022	96
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology	91
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021	88
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology	86
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology	79
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023	79
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology	79
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022	78
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021	77
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020	76
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020	63
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology	57
NCCN Guidelines Insights: Survivorship, Version 2.2020	57
Safety at the Time of the COVID-19 Pandemic: How to Keep Our Oncology Patients and Healthcare Workers Safe	57
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology	54
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023	54
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022	52
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022	51
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022	51
A Pilot Study of a Comprehensive Financial Navigation Program in Patients With Cancer and Caregivers	43
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022	43
Functional Impairment, Symptom Burden, and Clinical Outcomes Among Hospitalized Patients With Advanced Cancer	41
Impact of Telemedicine on Patient Satisfaction and Perceptions of Care Quality in Radiation Oncology	39
NCCN Guidelines® Insights: Palliative Care, Version 2.2021	38
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology	36
Survivorship, Version 1.2021	35
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022	35
Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma	33
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022	32
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer	32
Neoadjuvant Immunotherapy–Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series	32
Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology	32
Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review	32
Current Practices for Screening and Management of Financial Distress at NCCN Member Institutions	32
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience	31
A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status	31
Incident Cancer Detection During the COVID-19 Pandemic	30
Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma	30
Diagnostic and Therapeutic Delays in Patients With Hepatocellular Carcinoma	28
Conditional Survival and Cure of Patients With Colon or Rectal Cancer: A Population-Based Study	28
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021	28

Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology	27
Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab	26
Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor	26
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology	26
Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma	25
Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature	25
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors	25
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma	25
Local Recurrence and Disease-Free Survival After Transanal Total Mesorectal Excision: Results From the International TaTME Registry	25
Adolescents and Young Adults Living With an Uncertain or Poor Cancer Prognosis: The “New” Lost Tribe	24
Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer	24
NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023	23
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic	23
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer	23
Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes	23
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology	22
NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023	21
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022	21
Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy	21
Role of Postoperative Radiotherapy in Nonmetastatic Head and Neck Adenoid Cystic Carcinoma	21
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022	21
Outcomes and Predictors of 28-Day Mortality in Patients With Hematologic Malignancies and Septic Shock Defined by Sepsis-3 Criteria	20
Barriers to Optimal End-of-Life Care for Adolescents and Young Adults With Cancer: Bereaved Caregiver Perspectives	20
Pilot Randomized Trial of a Transdisciplinary Geriatric and Palliative Care Intervention for Older Adults With Cancer	20
Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib	20
The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer	19
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms	19
Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study	19
Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma	19
Effects of Postoperative Radiotherapy on Survival of Patients With Stage IIIA Resected Non–Small Cell Lung Cancer: Analysis of the SEER Database	19
Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer	19
Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease	19
Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment	18
PTCH1-GLI1 Fusion–Positive Ovarian Tumor: Report of a Unique Case With Response to Tyrosine Kinase Inhibitor Pazopanib	18
Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer	18
Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature	18
A Web-Based Tool to Automate Portions of Pretest Genetic Counseling for Inherited Cancer	18
Defining and Managing High-Risk Multiple Myeloma: Current Concepts	18
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology	18
Relationship Between Perceptions of Treatment Goals and Psychological Distress in Patients With Advanced Cancer	18
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023	18
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study	17
Association Between Chronologic Age and Geriatric Assessment–Identified Impairments: Findings From the CARE Registry	17
Experience, Perceptions, and Recommendations Concerning COVID-19–Related Clinical Research Adjustments	16
Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database	16
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer	16
Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer	16
Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer	16
Cross-Sectional Analysis of the Associations Between Four Common Cancers and Disability	16
Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score–Matched Study	16
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy	16
General and Health-Related Internet Use Among Cancer Survivors in the United States: A 2013–2018 Cross-Sectional Analysis	16
Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response	16
Cachexia and Dietetic Interventions in Patients With Esophagogastric Cancer: A Multicenter Cohort Study	16
Performance Status Restriction in Phase III Cancer Clinical Trials	15
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024	15
Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma	15
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II–III Breast Cancer: A Multicenter Value Analysis	15
Outcomes of Patients With Cancer Discharged to a Skilled Nursing Facility After Acute Care Hospitalization	15
Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy	15
Patient Satisfaction and Quality of Life Before and After Treatment of Pancreatic and Periampullary Cancer: A Prospective Multicenter Study	14
Inherited Mutations in Chinese Men With Prostate Cancer	14
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine	14
Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance	14
Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma	14
Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis	13
NCCN Guidelines® Insights: Survivorship, Version 1.2022	13
Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study	13
Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019	13
Association of Polypharmacy and Potentially Inappropriate Medications With Physical Functional Impairments in Older Adults With Cancer	13
Pediatric Hodgkin Lymphoma, Version 3.2021	13
Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults	13
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial	13
Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC	12
Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease	12
Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond	12
NCCN Guidelines® Insights: Distress Management, Version 2.2023	12
Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study	12
Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy	12
Re-Engage: A Novel Nurse-Led Program for Survivors of Childhood Cancer Who Are Disengaged From Cancer-Related Care	12

Including DPYD on Cancer Genetic Panels to Prevent Fatal Fluoropyrimidine Toxicity	12
Impact of Axillary Dissection Among Patients With Sentinel Node–Positive Breast Cancer Undergoing Mastectomy	12
The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook	11
Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis	11
Risk of Cardiovascular Diseases Among Older Breast Cancer Survivors in the United States: A Matched Cohort Study	11
Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation	11
Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial	11
Race- and Age-Related Disparities in Cervical Cancer Mortality	11
Patterns and Trends of Cancer Screening in Canada: Results From a Contemporary National Survey	11
Current Surveillance After Treatment is Not Sufficient for Patients With Rectal Cancer With Negative Baseline CEA	11
Prevalence of Insomnia in an Oncology Patient Population: An Irish Tertiary Referral Center Experience	11
Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology	11
Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance	11
Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer	11
The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?	11
Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice	11
Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer	10
Impact of Facility Surgical Volume on Survival in Patients With Cancer	10
Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia	10
Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer	10
Optimize Local Therapy for Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer to Enhance Survival	10
Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer	10
Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective	10
Immune-Related Adverse Events Among COVID-19–Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade	10
Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis	9
How Have Multigene Panels Changed the Clinical Practice of Genetic Counseling and Testing	9
Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials	9
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology	9
Tumor Mutation Burden and Depression in Lung Cancer: Association With Inflammation	9
Diagnosis and Management of Rectal Cancer in Patients Younger Than 50 Years: Rising Global Incidence and Unique Challenges	9
Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival	9
Challenges in the Histopathologic Diagnosis of Histiocytic Neoplasms	9
Prevalence of Anemia and Compliance With NCCN Guidelines for Evaluation and Treatment of Anemia in Patients With Gynecologic Cancer	9
Blastic Plasmacytoid Dendritic Cell Neoplasm	8
Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells	8
What’s in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia	8
Overuse of Diagnostic Brain Imaging Among Patients With Stage IA Non–Small Cell Lung Cancer	8
Serial Assessment of Urinary Incontinence in Breast Cancer Survivors Undergoing (Neo)Adjuvant Therapy	8
Optimal Neoadjuvant Strategies for Locally Advanced Rectal Cancer by Risk Assessment and Tumor Location	8
Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients	8
Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma	8
Improving Health Equity and Reducing Disparities in Pediatric and Adolescent/Young Adult Oncology: In Support of Clinical Practice Guidelines	8
Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma	8
Underperformance of Contemporary Phase III Oncology Trials and Strategies for Improvement	8
Associations of Skeletal Muscle With Symptom Burden and Clinical Outcomes in Hospitalized Patients With Advanced Cancer	8
Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States	8
Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes	8
Validating a Patient-Reported Outcomes–Derived Algorithm for Classifying Symptom Complexity Levels Among Patients With Cancer	8
Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative	8
Depressive Symptoms in Danish Patients With Glioma and a Cancer-Free Comparison Group	8
Methylene Blue for the Treatment of Intractable Pain From Oral Mucositis Related to Cancer Treatment: An Uncontrolled Cohort	8
Priority Rankings of Patient-Reported Outcomes for Pancreatic Ductal Adenocarcinoma: A Comparison of Patient and Physician Perspectives	8
Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation	7
Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis	7
Contemporary Population-Based Analysis of Bone Mineral Density Testing in Men Initiating Androgen Deprivation Therapy for Prostate Cancer	7
Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report	7
Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options	7
Update on Guidelines for the Prevention of Cancer-Associated Thrombosis	7
Integration of Pediatric Hodgkin Lymphoma Treatment and Late Effects Guidelines: Seeing the Forest Beyond the Trees	7
Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study	7
Treatment of Stage IV Colon Cancer in the United States: A Patterns-of-Care Analysis	7
Patient, Caregiver, and Oncologist Experiences With and Perceptions of Racial Bias and Discrimination in Cancer Care Delivery	7
Outcomes of Patients With Advanced Gastrointestinal Cancer in Relationship to Opioid Use: Findings From Eight Clinical Trials	7
NCCN Distress Thermometer Problem List Update	7
Paid Sick Leave Among Working Cancer Survivors and Its Associations With Use of Preventive Services in the United States	7
Association of Social Support With Overall Survival and Healthcare Utilization in Patients With Aggressive Hematologic Malignancies	7
Impact of the Extent of Lymph Node Dissection on Precise Staging and Survival in Clinical I–II Pure-Solid Lung Cancer Undergoing Lobectomy	7
Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel	7
Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal	7
Mobile Technology-Based (mLearning) Intervention to Enhance Breast Cancer Clinicians' Communication About Sexual Health: A Pilot Trial	6
Medicare/Medicaid Insurance, Rurality, and Black Race Associated With Provision of Hepatocellular Carcinoma Treatment and Survival	6
Surgery After Response to Chemotherapy for Locally Advanced Pancreatic Ductal Adenocarcinoma: A Guide for Management	6
The Microbiome Colorectal Cancer Puzzle: Initiator, Propagator, and Avenue for Treatment and Research	6
Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology	6
Expanding the Use of Nephron-Sparing Surgery for Wilms Tumor	6
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer	6
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors	6
Patients With cT1N0M0 Oral Squamous Cell Carcinoma Benefit From Elective Neck Dissection: A SEER-Based Study	6
Evaluating if an Advance Care Planning Intervention Promotes Do-Not-Resuscitate Orders by Facilitating Accurate Prognostic Awareness	6
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer	6
Cancer Treatment During COVID-19: Resilience of Individuals With Advanced Non–Small Cell Lung Cancer Versus Community Controls	6
Breast Cancer Diagnostics, Therapy, and Outcomes in Sub-Saharan Africa: A Population-Based Registry Study	6
Quality of Life Is Associated With Survival in Patients With Gastric Cancer: Results From the Randomized CRITICS Trial	6
Low Rates of Chemotherapy Use for Primary, High-Grade Soft Tissue Sarcoma: A National Cancer Database Analysis	6
Sex- and Age-Related Differences in the Distribution of Metastases in Patients With Upper Urinary Tract Urothelial Carcinoma	6
NCCN Guidelines® Updates: Kidney Cancer	6
SOURCE: Prediction Models for Overall Survival in Patients With Metastatic and Potentially Curable Esophageal and Gastric Cancer	6
Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines	6
Metastatic Spiradenocarcinoma Managed With PD-1 Inhibition	5
A Survey of the National Comprehensive Cancer Network on Approaches Toward Addressing Patients’ Transportation Insecurity	5
Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale	5
Risk of Cancer-Specific Death for Patients Diagnosed With Neuroendocrine Tumors: A Population-Based Analysis	5
Comorbidities, Rather Than Older Age, Are Strongly Associated With Higher Utilization of Healthcare in Colorectal Cancer Survivors	5
Elderly Black Non-Hispanic Patients With Head and Neck Squamous Cell Cancer Have the Worst Survival Outcomes	5
Representation of Sexual and Gender Minority People in Patient Nondiscrimination Policies of Cancer Centers in the United States	5